Lancet Oncology
Papers 8443
1 page of 845 pages (8,443 results)
#1Panagiotis A. Konstantinopoulos (Harvard University)H-Index: 34
#2Su-Chun Cheng (Harvard University)
Last. Marta A. Crispens (Vandy: Vanderbilt University)H-Index: 16
view all 24 authors...
Summary Background High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S phase entry (due to CCNE1 amplification, RB1 loss, or CDKN2A mRNA downregulation), alterations of homologous recombination repair genes, and expression of oncogenic drivers (through MYC amplification and other mechanisms). We hypothesised that the combination of ...
#2Jennifer G. Whisenant (VUMC: Vanderbilt University Medical Center)H-Index: 11
Last. Anna Cecilia BettiniH-Index: 3
view all 50 authors...
Summary Background Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies. ...
1 CitationsSource
#1Hisham M. Mehanna (University of Birmingham)H-Index: 32
#2John Hardman (National Health Service)
Last. Andreas Dietz (Leipzig University)H-Index: 36
view all 48 authors...
Summary The speed and scale of the global COVID-19 pandemic has resulted in unprecedented pressures on health services worldwide, requiring new methods of service delivery during the health crisis. In the setting of severe resource constraint and high risk of infection to patients and clinicians, there is an urgent need to identify consensus statements on head and neck surgical oncology practice. We completed a modified Delphi consensus process of three rounds with 40 international experts in he...
1 CitationsSource
#1Jean-Yves BlayH-Index: 78
#2César SerranoH-Index: 10
Last. Gina Z. D'Amato (UM: University of Miami)H-Index: 1
view all 17 authors...
Summary Background Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours. Meth...
#1Gilles Salles (University of Lyon)H-Index: 78
#2Johannes DuellH-Index: 10
Last. Marc André (UCL: Université catholique de Louvain)H-Index: 25
view all 17 authors...
Summary Background Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options. Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide. We aimed to assess the a...
1 CitationsSource
#1John Kuruvilla (Princess Margaret Cancer Centre)H-Index: 27
#1Carlotta Antoniotti (UniPi: University of Pisa)H-Index: 15
#2Chiara Cremolini (UniPi: University of Pisa)H-Index: 29
Last. Alfredo Falcone (UniPi: University of Pisa)H-Index: 51
view all 4 authors...
Top fields of study